Patients and the public experienced rapid availability of new vaccines and treatments against COVID-19 infections during the pandemic in 2020. Although it is obvious that this was due to exceptional circumstances, it has raised the expectations for shorter development times for future medicines. Therefore, time pressure on clinical researchers and regulators has further increased and calls for innovation and creativity. In the EUFEMED 2023 conference we will discuss options and strategies for Mastering the New Time Pressure on Human Pharmacology in order to achieve shorter timelines in early medicines development.
Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD
November 12, 2026
NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.
Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in 14–16 November 2026, on 14–16 November 2026, hosted by the American Heart Association.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
